Posted by Michael Wonder on 13 Feb 2020
FDA grants Soligenix fast track designation for RiVax in the prevention of ricin poisoning
13 February 2020 - Soligenix announced today that its RiVax (heat stable ricin toxin vaccine) development program for prevention of ricin intoxication has received fast track designation from the US FDA.
The development of RiVax has been funded through a series of grants from both the National Institute of Allergy and Infectious Diseases (NIAID) and the FDA and ongoing development is sponsored by NIAID contract #HHSN272201400039C.
Non-dilutive funding for the development of RiVax has exceeded $40 million to date.
